Niki BioSolutions, Inc.
NIKI Nasdaq· Measuring & Controlling Devices, Nec
Last close · Oct 30, 2026
$1.77
KIRA · Stoqly’s AI analyst, in plain words
- Niki BioSolutions, Inc. lost $1.4M in fiscal 2025.
- Operating cash flow was −$1.8M in fiscal 2025. At that burn of $1.8M a year, its $3.5M of cash and short-term investments would last about 1.9 years.
Market cap
$13.0M
P/E
—
Revenue
—
Net income
−$1.4M
Free cash flow
—
Operating margin
—
Niki BioSolutions, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$1.4M
No. It lost money last year.
How long would its cash last?
1.9 yrs
For now. It burns $1.8M a year and holds $3.5M, about 1.9 years at that pace.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Niki BioSolutions, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 27, 2026
- Legal name
- Niki BioSolutions, Inc.
- CIK
- 0001734005
Niki BioSolutions, Inc. · NIKI · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.5M | $1.3M | $0.4M | — | — |
| Revenue growth | — | −15.9% | −66.7% | — | — |
| Gross margin | 5.3% | 6.2% | 2.5% | — | — |
| Net income | −$25.0M | −$9.8M | −$2.8M | −$4.3M | −$1.4M |
| Net margin | −1,624.6% | −756.2% | −654.8% | — | — |
| Diluted EPS | −$7.15 | −$2.75 | −$0.62 | −$0.78 | −$0.19 |
| Cash | |||||
| Cash from operations | −$14.7M | −$12.3M | −$7.7M | −$1.2M | −$1.8M |
| Capital expenditure | $0.1M | $0.2M | $0.0M | — | — |
| Free cash flow | −$14.8M | −$12.5M | −$7.7M | — | — |
| FCF margin | −958.8% | −965.0% | −1,791.2% | — | — |
| Share count change | 11.1% | 1.9% | 26.7% | 20.6% | 34.8% |
| Debt and strength | |||||
| Cash and short-term investments | $8.5M | $5.1M | $2.0M | $0.9M | $3.5M |
| Debt incl. finance leases | $0.3M | $0.1M | — | — | — |
| Shareholders' equity | $23.6M | $15.7M | $24.8M | $21.1M | $23.1M |
| Current ratio | 2.9x | 0.6x | 1.2x | 0.2x | 0.8x |
| Returns and quality | |||||
| Return on equity | −76.6% | −49.8% | −13.9% | −18.6% | −6.2% |
| Return on tangible equity | −110.2% | −65.5% | −11.4% | −20.2% | −5.9% |
| Piotroski F-score | 1 | 3 | 2 | — | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Niki BioSolutions, Inc. · NIKI · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.77 a share, the company is worth $13.0M.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001734005). Latest version: stoqly.net/companies/niki. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.